Antihypertensive Strategy for Chest Pain with Bradycardia

Medication Selection

ACE inhibitors (e.g., low‑dose lisinopril, captopril, ramipril) or ARBs (e.g., valsartan) should be initiated first to provide cardiovascular protection without markedly lowering heart rate in patients with chest pain and a heart rate < 60 bpm. 1
Dihydropyridine calcium‑channel blockers (amlodipine or nifedipine) are the preferred adjunct because they reduce blood pressure without a negative chronotropic effect and are safe even in severe heart failure. [4][5]
If additional blood‑pressure control is needed, thiazide or thiazide‑like diuretics can be added as third‑line therapy. [4][5]

Beta‑blockers (e.g., metoprolol, carvedilol, bisoprolol) are contraindicated when the heart rate is < 60 bpm because they can precipitate severe bradycardia, high‑grade AV block, and cardiogenic shock. The 2013 ACC/AHA STEMI guideline explicitly recommends avoidance in this setting. 1
Non‑dihydropyridine calcium‑channel blockers (diltiazem, verapamil) should be avoided as they further depress heart rate and may cause high‑grade AV block. [1][6]2
Clonidine is not recommended in patients with heart failure due to adverse hemodynamic effects. 6

For ongoing chest pain with hypertension, sublingual nitroglycerin 0.4 mg every 5 minutes (up to three doses) may be used provided systolic blood pressure remains ≥90 mmHg and no phosphodiesterase‑inhibitor has been taken in the prior 24–48 hours. 1

Heart‑failure patients: The 2025 European Heart Failure Association advises starting an SGLT2 inhibitor and a mineralocorticoid‑receptor antagonist first (minimal impact on BP/HR), followed by low‑dose ACE inhibitor/ARB or very low‑dose sacubitril/valsartan (25 mg twice daily). Beta‑blockers may be added only after heart rate rises above 70 bpm; ivabradine is an alternative for rate control. 7
Post‑myocardial infarction: ACE inhibitors are strongly indicated for anterior infarction, left‑ventricular dysfunction (ejection fraction ≤ 0.40), or overt heart failure. Beta‑blockers should be introduced only after heart rate normalizes, as early use in bradycardic patients raises the risk of cardiogenic shock despite benefits in reducing recurrent MI and ventricular fibrillation. 1

Medications should be titrated slowly, using small increments and introducing one agent at a time. 7
Monitor for hypotension; avoid diastolic blood pressure < 60 mmHg in patients with coronary artery disease. [6][2]
Target blood pressure <130/80 mmHg, with a possible goal of <120/80 mmHg in the presence of ventricular dysfunction. [6][2]
Reassess heart rate regularly; if it rises above 70 bpm, a beta‑blocker may be cautiously added for additional cardiovascular protection. 7